Phase 1 dose-escalation trial on track; preclinical combination data with anti-PD-1 antibody demonstrates potential for ...

Add Yahoo as a preferred source to see more of our stories on Google. Weather and sea conditions could delay crews getting to the Longships Lighthouse to do the repair - Matt Cardy/Getty Images A ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

The market expects Foghorn Therapeutics Inc. (FHTX) to deliver a year-over-year increase in earnings on higher revenues when ...

Foghorn Therapeutics Inc. (FHTX) came out with a quarterly loss of $0.29 per share versus the Zacks Consensus Estimate of a loss of $0.28. This compares to a loss of $0.3 per share a year ago. These ...

Foghorn Therapeutics, a biotech whose technology can affect one of the ways a cell regulates gene expression, has shown its approach has the potential to address a particular mutation tied to more ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

NARRANGANSETT, R.I. (WJAR/CNN Newsource/WKRC) - Imagine going for a walk in the park, getting some work done, or even going to sleep, all while a loud foghorn blares through your town every 30 seconds ...

As Foghorn Therapeutics battles to free a trial from an FDA clinical hold, the biotech is now facing a partial hold for another program—meaning the company's two clinical assets are now tied up in red ...

SUNNYVALE, Calif.--(BUSINESS WIRE)--FogHorn, a leading developer of edge computing AI software for industrial and commercial Internet of Things (IoT) solutions, today announced plans to collaborate ...